ADL5859
- Generic Name
- ADL5859
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
- Indication
Investigated for use/treatment in pain (acute or chronic).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2015-08-14
- Target Recruit Count
- 408
- Registration Number
- NCT00979953
- Locations
- ๐บ๐ธ
Covance CRU, Inc, Daytona Beach, Florida, United States
๐บ๐ธAtlanta Knee and Shoulder Clinic, PC, Stockbridge, Georgia, United States
๐บ๐ธColumbus Clinical Research, Columbus, Ohio, United States
Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2015-07-01
- Target Recruit Count
- 46
- Registration Number
- NCT00626275
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit Inc., Daytona Beach, Florida, United States
๐บ๐ธNew England Research Associates, Trumbull, Connecticut, United States
๐บ๐ธThe Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2015-07-01
- Target Recruit Count
- 226
- Registration Number
- NCT00603265
- Locations
- ๐บ๐ธ
Advanced Regional Center for Clinical Research (Ankle & Foot Care), Altoona, Pennsylvania, United States
๐บ๐ธAquilo Research, Yukon, Oklahoma, United States
๐บ๐ธPanhandle Family Care Associates & Emerald Coast Research Grp, Inc., Marianna, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.